Dr. Brentjens on the Side Effects of CAR-Modified T Cells

Video

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)–modified T cells when used to treat B-cell malignancies.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor(CAR)—modified T cells when used to treat B-cell malignancies.

Brentjens says that only patients with a significant amount of disease in their bone marrow developed fevers, low blood pressure, and high heart rate.

The symptoms are likely caused by cytokines, Brentjens says, which are hormones that are secreted by the T cells. When the T cells are infused into the patient, they go into the marrow, recognize the tumor cells, and become activated. Once T cells are activated, they secrete cytokines, Brentjens says.

Brentjens says patients with a large amount of tumor cells require more T cells to activate, resulting in more cytokine secretion. Patients that only have a slight amount of disease left will not have high cytokine levels, and thus, no side effects.

Brentjens says this correlation has led doctors to treat patients with CAR-modified T cells only when they have the minimal amount of disease.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.